Clinical trials: Anlotinib
Lung Neoplasms, Docetaxel
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Conditions
- Lung Neoplasms, Docetaxel, Pemetrexed, S-1
- Trial name
- NCT03589950
- Testing
- anlotinib plus chemotherapy, chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First People's Hospital of Lianyungang
Gastric Cancer, Colo-rectal Cancer
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.
- Trial name
- NCT04777162
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Multiple Myeloma
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in relapsed or refractory multiple myeloma…
- Trial name
- NCT05549973
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lung Cancer, Lung Carcinoma
Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients
This prospective observational study will evaluate the efficacy and safety of anlotinib in combination with Penpulimab in elderly patients with lung cancer.
- Conditions
- Lung Cancer, Lung Carcinoma, Non Small Cell Lung Cancer, Non-small Cell Carcinoma
- Trial name
- AP (NCT05319886)
- Testing
- Anlotinib and Penpulimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Non Small Cell Lung Cancer
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer.
- Trial name
- NCT05913089
- Testing
- TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule
- Where
- 10 sites in China
- Volunteers
- 58 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unresectable Stage III Non-small Cell Lung Cancer
A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT04111913
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
NSCLC, Anlotinib
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
- Conditions
- NSCLC, Anlotinib, PD-1/L1 Inhibitor
- Trial name
- NCT04313660
- Testing
- Anlotinib In Combination With PD-1/L1 Inhibitor
- Volunteers
- 33 people
- Sponsor
- Xiaorong Dong
Non-small Cell Lung Cancer, EGFR Gene Mutation
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
TKIs therapy is the first-line treatment of patients with EGFR mutation advanced NSCLC.However, some patients have poor prognosis of drug resistance in the early stage.
- Trial name
- NCT04358562
- Testing
- Gefitinib, Anlotinib
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy.
- Trial name
- NCT04004572
- Testing
- LEAP regimen
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Rong Tao
Triple Negative Breast Cancer
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
This is an open-label, single-arm, multicenter phase I/II study to evaluate the safety and efficacy of sac-TMT plus anlotinib in previously treated mTNBC. The study is expected to enroll up to 59 eligible patients.
- Trial name
- NCT07139470
- Testing
- Sacituzumab Tirumotecan + anlotinib
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma
- Trial name
- NCT03825705
- Testing
- TQB2450 injection, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Esophageal Squamous Cell Carcinoma
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
- Trial name
- ANSWER (NCT05214222)
- Testing
- Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma, Adjuvant Therapy
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
This is An Open, Single Arm, Multicenter, Exploratory Phase II study, to evaluate the efficacy and safety of TQB2450 Plus anlotinib as adjuvant therapy in hepatocellular carcinoma(HCC) patients at high risk of recurrence after…
- Trial name
- ALTER-H006 (NCT05111366)
- Testing
- TQB2450 injection, Anlotinib hydrochloride capsules
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Xianhai Mao
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Non Small Cell Lung Cancer
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus K drug as a first-line treatment of advanced non-small cell lung cancer.A total of 375 subjects will…
- Trial name
- NCT04964479
- Testing
- TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection
- Where
- 17 sites in China
- Volunteers
- 375 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Nonsmall Cell Lung Cancer
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride…
- Trial name
- CSOAIMTOAN (NCT03769805)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 83 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage
Anlotinib in Cross-line Treatment of NSCLC and SCLC
Previous studies on bevacizumab in colorectal and ovarian cancers have demonstrated that continued anti-angiogenic therapy after disease progression can still provide clinical benefits.
- Trial name
- NSCLC SCLC (NCT07400575)
- Volunteers
- 350 people
- Sponsor
- Henan Cancer Hospital
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Pucotenlimab and Anlotinib in Combination With Chemotherapy
A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer.
- Trial name
- NCT07896668
- Testing
- LP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital